Вы находитесь на странице: 1из 37

1

514534

4
6
8
10

16

28583

28584
18
25385
25386

22

22791

22793
26 3

15397
28 -

25414
30

22794

22795
32

22465

22467 3

36

23473

46
54 -
57 -

| 2016

22138
15448
15447



,
, , .

.
15
, .

, ,
.

,
. ,
!

12


62
3

,
.
.

| 2016

:
22.
, ,

.

50
,

.


2014.
,


2015.

,
NovAge Ultimate Lift.range.

,


,

, .


,
.

, ,
.

:

.

,
...,
,

,

,
.

.


.
200
,
, ,

,

.

, ...

, ,
.

... ,
,
, 1988.

,
..., -
,

14

.

,
.
2010,


.


, ...,
,
,


Haematococcus pluvialis

AstaReal, .



.

,


.

-.

, ...,

,

, ,
.



.
/
120 , 14
,
24 .


2001.


2009.

,
,


.10

,
..,

,
,

,
,

(

),

,
, .

.

GMP

GOOD
MANUFACTURING
PRACTICE


FOS




,
,
,


.

| 2016

-
.

,

,

.

( )
.
,
, , .

HACCP

GOOD
MANUFACTURING
PRACTICE

( )
,
, .

,
,
.
2009.

ISO/IFS/BRC

GMO
PRODUCT


(EUGMO).
1829/2003 1830/2003.

NON-

, ISO ( ), IFS ( )
BRC ( ),
.

GMP

GMP


FOS

FRIEND OF
THE SEA (FOS). (),
.
, ,

. FOS ,
,
. FOS

.

(KA)
() 1974.
.

, ,
,
.



. - ,
,
.

| 2016

FRIEND OF THE SEA


:
1974
1981, 1988
, 1987
, 1997

| 2016


(Resuscitation 2002; 2003; 2004);
(ERC):
, 2002;
ex vivo
70- , 2005 (Ann Thorac Surg 2007).
:
LUCAS,
Medtronic (www.jolife.com);
ex vivo STEEN Solution (www.vitrolife.com);
, 48 , Vivoline LS,
Vivoline Medical AB (www.vivoline.se),
;
.


2017 .

.
MCCIR (
)
, . 2015
,
.

, ,

10

:

ex vivo, 2000 (Lancet 2001);

4-
28
,
..

, 1997, 2000,
, , 2001

: | : 07.02.1948

, , .
.
, , , , ;

, .

,
.
,

,
, -
, .

,
, . .
,
1998,
.
.

11



,
.

12

| 2016

, ,
40 !

,
. .

,
,
.

NB PRODUCTS

, -
,
, ,
.
,
,
.

13


1,5-2

,

NON22138

15447

15448

GMO
PRODUCT

65

: , ,
( ), , ,
, , ( )
().
: , ,
, ( ), ,
, , , (
), ( ) ().
: , ,
, ( ), -,
, , ,
, ( ) ().

14

| 2016

15





,
,
,


.

NON-

70

28584

28583

GMO
PRODUCT


, , ,

: , ,
, , , , ,
, , ,
, (), , .
: , ,
, , , , ,
, (), , (0,4%),
, ( ), .

16

| 2016

17

NON-

GMO
PRODUCT


7,5 1

25385

25386


,
150

: (18,7%),
, , , ,
( , , ), ,
, , 4,3% (
(), , , ( ,
, ), (), ,
( , ), ),
(3%), ( , , , ,
, ), ( ), (
), ( ). , .
, .

18

: (17,3%),
, , , (
, , ), , (,
, , ( ), ) 6,3%,
, , , (2,8%),
(2,8%), ( , , , ,
, ), , , .
, .
, .

| 2016


4 1

19

PDCAAS

PDCAAS

1.00

1.00

( )

1.00

0.92

0.82

0.52

: . . . . (). . Pulse Canada, www.pulsecanada.com

012345

012345

| 2016

() , ,
:

( , ),
.
,
.
,
.

, 100.
55 . 56-69
, , 70
.
.

, .
,
. ,
,
, ,
,
.
, .

20

, ,
,
. , ,
, ,
, .
, . ,
, .
(WHO)
(FDA)
(PDCAAS), .

,
(). ,
,
, .
,
,
, .
.
, : , , .
.
() .
,
, .
,
( ).
.

= =
21

| 2016

22

,
.

,
, ,
.
,
, .
,
. . 90-
,
.
, ,
,
, ,
, -,
.
: -3,
. , -3 ( )
- .
: -3
.

, .
,
.
,

.

23

GMP

GOOD
MANUFACTURING
PRACTICE


 :

:
2 -3
: 150 , 100 , 290
-3 . ,
.
26-27.
1 -
: 3 , 50
,
.
.
28-29.
1


.
30-31.

( 3)
.

( 3)
.

| 2016

22791

, D .

, , , ( B3),
, , B12, B6
.

24


, , , , , 12, 6,
, D,
.
,

*.
,

*.

22793

.
,

( ),
*. ,

( ),
, *.


FOS

( B7), , ( B3), (
B2),
.

.
,
.
,
, *.

* . 42

25

(. . 24)


FOS

-3:

-3

GMP

GOOD
MANUFACTURING
PRACTICE

15397



.
.

| 2016

100%
.

26


FOS .

: , , . : 693 .
:
2 :
1000 **
150 , 100
**
-3
,
.

-3 , . -3 ,
, , ,
.

-3 ()
(). -
, . 3, ,
0,2 15%, .

.


,
-3
.

-3


,
.

(-3- )
.

27

GOOD
MANUFACTURING
PRACTICE

,
*:

25414




( ).

( )*.

| 2016

,
, ,

-3 -6

* . 42

:
:
3 **
50 **

** .

- ,
.


,
,
. , ,
,
.


,

.
,

.


.

,
,
, .


.
,
,
-
.


-
.

28

: 720 .


(), -

: , , , ,
(), ( ),
.



()

GMP

 (. . 24)

29

GMP

GOOD
MANUFACTURING
PRACTICE

( . 24)


, , , , ,
, B12, B6
.


,
?

%

( 2008 )

A
D
B1 ()

B2 ()
B3 ()
B5 ( )
B6 ()
B9 ( )
B12 ()











1.6
5
1.1
12
1.4
16
6
1.4
200
2.5
80
50
150
100
2
150
1
7
10
55
50
40

1.4
5
1.1
12
1.4
16
6
1.4
200
2.5
80
50
135
75
2
150
1
14
7
40
50
30

100
100
100
100
100
100
100
100
100
100
100
100
19
27
100
100
100
50
100
100
100
100

87.5
100
100
100
100
100
100
100
100
100
100
100
22
20
100
100
100
100
70
73
100
75

30

| 2016

, D
.

22795


, , , , , 12, 6,
, D,
.

22794

( B7), , ( B3),
( B2) .

.

31

GMP

GOOD
MANUFACTURING
PRACTICE


-3:

| 2016

1 (5 = 4,6 )
1.2
1.1
2.3
-3
1.4
0.7
0.5

5.5 *46%
:
(99%), , (DL-- ),
( ), .
:
(5 ) .
*%

32

,
FRIEND OF THE SEA

-3


, ,
-

22467



.
.


FOS


,
3
.
,
,
. ,

,
.

-3

33

GMP

GOOD
MANUFACTURING
PRACTICE


27996

A
D
E
K
B1 ()
B2 ()
B3 ()
B5 ( )
B6 ()
B9 ( )
B12 ()

C








300
2.5
5
20
0.5
0.5
6
2
0.5
100
0.9
8
30
120
60
75
3
4
13
20
15


4-6
7-9
450
5
5
20
0.6
0.6
8
3
0.6
200
1.2
12
30
600
76
*150
4.2
4.8
22
*50
*40

500
5
7
25
0.9
0.9
12
4
1.0
300
1.8
20
35
700
100
*150
5.9
5.6
21
*50
*40

:
3-9 , 10 .

34

| 2016

* , .
.
35

GMP

GOOD
MANUFACTURING
PRACTICE


,
28507


, .
L-
,

L-
,

| 2016

:
.
12 .
.
.

36

: (L- , , L-
, , , , ),
( ( ,
), , ( ,
), (, )).

,
, .
.

L-
, ,
.

37

: .

.
.
, , (-), ,
. - ,
.

| 2016

.
, , .
- ,
, , (,
).

38

,
., , , ,
,
.

.

, ,
, , .

. , , ,

.

D , ,
,
.
D : ,
10 . ,
D c . D
, .

B B,
, ,
.

,
-

. B
, , , ,
, , .

1. (A, D, E K), ,
, , ,
. A
,
.
/ , K
.

2.
( )
, .
,

. ,
, .

,
,
,
.

39

:
,
.
, , , ,
(
).

, .
, ,
, .
, , , ,
.

| 2016


(3) (4), , ,
. ,
.
. ,
, , , , .

,
,
( ).
, ,
. ,
.

, ,
, , , , .
, , , ,
, , .

,
, ,
.
,
, ,
,

. :
, , .

40

, ,
,
.
, .
: , , , , .


.

, ,
.
: , , ,
.

300 ,
, ,
. ,
.
, ( ), .
, ,
, .

- .

.
,

. ,
,
,
.
, , ,
.

, , , , ,
(
).


,
, ,
( ,
,
),
.
, , , .

41


. ,

() . ,
, , .

Iwamoto T et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb


2000;7(4):21622.
Yoshida H et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in
subjects with mild hyperlipidemia. Atherosclerosis 2010;209(2):5203.
( .: . J Atheroscler Thromb 2000; 7 ( 4 ): 216-22.*)

| 2016

Karppi J et al. Effects of astaxanthin supplementation on lipid peroxidation. Int J Vitam Nutr Res
2007;77(1):311.
( .: *. Int J Vitam Nutr Res
2007;77(1):3-11.)

, ,
, .
,
.

Tominaga K et al. Cosmetic benefits of astaxanthin on humans subjects. Acta Biochim Pol 2012;59(1):437.
( .: . Acta Pol 2012; 59 ( 1 ): 43-7.*)

Kishimoto Y et al. Astaxanthin suppresses scavenger receptor


expression and matrix metalloproteinase activity in
macrophages. Eur J Nutr 2010;49(2):11926.
( .:

. Eur J Nutr 2010; 49 (2): 119-26.*)

,
,
,
,
,

.

Malmsten CL and Lignell A. Dietary supplementation with astaxanthinrich algal meal improves strength endurance a double blind placebo
controlled study on male students. Carotenoid Sci 2008;13:2022.
Sawaki K et al. Sports performance benefits from taking natural
astaxanthin characterized by visual activity and muscle fatigue
improvements in humans. J Clin Ther Med 2002;18(9):7388.
( : ,
-
. Carotenoid Sci 2008; 13: 20-22.
( .:

.
J Clin Ther Med 2002; 18 (9): 73-88.*)
* .

42

3 6 ,
( ).
. ,
(3) (6)
.

,
,
. ,
., ,
.

-
. , .,
( ).
, ,

( )
.

Camera E et al. Astaxanthin, canthaxanthin and beta-carotene differently


affect UVA-induced oxidative damage and expression of oxidative stressresponsive enzymes. Exp Dermatol. 2009;18(3):22231.
( . , -
- -
.*)

Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in
humans. Nutr Metab (Lond) 2010;7:18.
( , *.)

. ,
() (),
-.

43

50

| 2016

44

52
54
56
57
58
60
62



-TM

-


46
48

45

| 2016

,

,



:

,



.



,

,
.

:


,
,




:
, 150

,



,
.

?
, -TM -TM, , ,

-?
-TM ,
( , , , )
.
, . -TM,
.

46

-?
, , ,
,
. ,
,
, (, TM) ,
. , -TM,
.
, ,
.
, , , .


.
,
,

. -TM ?
-TM,
, ,
, , ().
,
.
3, ,
.
, , ,
, ,
- . ,
. ,
.

, , .
,
, ,
. ,
: ,
70 .

47

78

70
0

12

| 2016


12 7,5.

8 15.
5,6%,

12% .

84

48


,
, .

1500,
,
,


.

,
, ,
.
-
1 .


, ,

.


.


,
: , , .


10000 .
:
3060
,
,
.



,
,
,
.
.


.

()

(11 , 20 67 , 25,
138,9/2) 12 .

,
,

.
,
.
13 /
7,5 12 .
5,6%.

.
, ,
.

49

-TM

1
1
+
. . 52


(20 )
(70 )
(50 )
1/4
(20 )
: , ,
, (100 )
(2 . )
,
(150 )

(, ) (150 )


1 (150 ) (10 )
1



10000 .
.

, .
.

,

.

.

: 1-2

:
1
+


(20 )
(50 )
(70 )
(100 )
: , ,
, (100 )
2 .
, (140 )
(100 )

| 2016


- (
1 1
).
: ,
, .

/ .
(
) , .
,
. ,
.
.
/
.

50



1
/
(300 )
1
(50 )
(50 )


C
1 (150 ) (10 )
1

,
.
, , 3
,
.

51

:
,
.
, , 3
,
.

1
1
+

3/4
1/8
1/8

: 1-2

:
1
+

1 C
1
( 85 )
1 + 1

( 515 )
400

250
52

-TM
( 20 )
73
(30 ) 75

80
(15 )
90
(40 )
12
(20 )
25
(50 )
7
(70 )
20
(100 )
18
400

:

1500



3060 .
10000 .
3
: ,

30 .
.

,

.

.

!

| 2016



70
1 (150 ) (10 ) 145
1
150
125

500


(40 )
12
(70 )
20
(100 )
18
: , ,
, (200 )
130
(2 . )
80

(100)
135
(150 ) 105
500


- ( 1
1
).
- ( 1
).
: ,
, 12 .


.
(
) ,
.
,
.
, .

.
.

.

.
,
.
20 .

,
- .

-TM

350

-

10
1 65
/
5
(300 )
120
1
103
(50 )
19
(50 )
28
350


70
1 (150 ) (10 ) 145
1
150
125

+
.
. 52

53

-
-

1 + 1 +
(, , , , )

-



:
1 K
(100 )
(200 )


:

10
65
5
135
80
19
28
350

10
65
100
125
65
365




10
(30 ) 110
(200 ) 100
1 K 65
( )
(100 )
55
:
340



K
/
,
(200 )
(50 )
(50 )
:

PROGRAMS

54


10
1 K
(150 )
65

:
2
170
(30 )
12

(30 )

30
(50 )
10
(50 )
27
(30 )
36

360

| 2016

55

, ,
.

,
.



.

.

.

, ,
()
, ()
, ,
-

( )
,
,
,
,


(, ,
)


(, ,
)

- c
10
4
: 350-400
:
(, , ,
-)

//-
///


(, , , ,
)

( )

( )

( ) 73
(30 ) 75

80
(15 )
90
(40 )
12
(20 )
25
(50 )
7
(70 )
20
(100 )
18

400

56

| 2016

.
,
.

,
.

1 (1/2 )
2 (1/4 )

+
3 (1/4 )

C

,
.

,
.

1 (3/4 )
2 (1/8 )

+
3 (1/8 )

57


, , () , .
10 :
1. .
, , .

2. .
- ,
.
!
3. .

.

4. - , , , .
,
- .
,
, .

7. .
.
8. .
, , .
.
9. .
, , ,
, .
10. .
, , , ,
!

3045
, : ,
,
.
/ :
50%

, ,
, , .

40%:

, ,
, ,
.
, .

10%:

58

6. .
,
.
.

| 2016

5. .
, 2000 K ,
, , .

59

, , .
360 .

FPO

HEALTH & WEIGHT

!
10.
,

..

.

!
,
. ,
, , .
, , ,
.

FAQ

| 2016

!

.

,
, ,
, ,
, , ,
, .

, ,
. ,
.

BEAUTY SOLUTIONS

60

EVERYDAY

HEALTH

!
.

.

.

-
.

!
,
.
,
,
, ,
.

SCIENCE

BEHIND

61

FAQ

| 2016

?
.
(, , ), .
,
.
,
.
?

, .
?
, .
?
(, ),
,
. ,
.
.
, ?

.
, ,
10 .
, , ,
.
?
, , ,
.
6 , 3,5 .
/ , ,
,
. , . ,
.
?
,
, .
,
.
?

, ,
. , ,
. ,
600 . ( 0,08%)
.
(SCF) 1987, 1988, 1989 2000.
15 .
(FDA)
5 . (18 )
12,6 . , 70
28 .
, - ?
- , ,
.

62


?
,
, ,
. ,
, , 3 ,
. ,
.
, ,
, . 65 .
(
),
, . , ,
, .
, ,
. ,
.
?
,
.
.
() ?

. , (,
), ,
, .
, (,
), , , ,
. 55.
,
. ,
. , , ,
. 28.
?
, ,

.
. ,
, .
.
. , ,
, ,
.

:
1) , (
);
2) , (,
- ).
?
, , ,
. ,
, , .
, , .

63

| 2016



?
,
/, ,
,
.
(, , ,
..)?

. ,
200 .
. ,
3 - ,
.
?
, . (
, ). ,
, .
.
?
, . , .

64


?
, -
.
.

.
.
?
.
.
/.
?
, .
.
. .
.
?
,
. , .
?
, .
(=50). 1012 , 46
. ,
. /
.
. ?
, () ,
. ,
.
?
, . , .
.
, .


?
.
,

, ?
! (=40),
8 ,
. , ,
, () .
?
, , = 40.
18, 11 .
, - .
/ .
?
, , , ,
.
?
, .
?
. , .
?
,
.
- .
.
?
. ,
. , , ,
.

?
, , 14- .
-
, ?
, : , , ,
..
, , ( )
, -, .
?
,
.

65

| 2016

66

-
?
,
, , , ,
, (, , , ).
:
() .
, ,
.
, .
,
, . ,
. ,
( )
. ,
.
?
,
- ,
, .
.
,
.
, ,
.
?

. ,
:


.

E?
, , ,

. ,
,
. ,
,
. ,
.
?
, . ,
, ,
, , .. ,
UVA UVB. ,
, .
UVB . UVA
, ,
. :
,
.
?
,
. ,
. : ,
, , . ,
, .
, , .
, ,
. ,
.
, , ,
.
?

(-, , ),
e : , , , .
.
, . (
). , ,
. , ,


. ,
, .
?
, .
,
( ).
: ?
( )
. , , ,
(, , ). ,
.
, 3,
.

?
, .
, , .
, -
, ., (,
), .

?
,
, 3. ,
3 .
.
,
/ / .
?
.
. 12
, .
. -
14.

67

| 2016



?
, . ,
: , , .

, 3
?
, .
,
,
.
3 ?
3,
, .
, , ,
, , , .
?
, . , , .
. ?
,
. .
/ .
?
. ,
,
A. C ,
,
.

/
?
/
,
.
(, ). ,
, .
.
?
, .
, , .
, -
, ., (,
) .

68

3
3?
, , .
3 , , ,
.
, ,
( ) - .
, , , ,
, , .
3 ?
,
, , 250. 3
.
3 ?
,
3.
.
.
.
3 ?
, ,
, .
, . ,
,

. , ,

.
. ,
?
. 3, ,
, .
.
3?
, , , .
3 .
3 ?
. 3

, , , ,
. ,
, , .
3 , ?
3.
: () (),
- (),
.
- , .
-
3 , .

?
,
.
, ,
.
?
.

, .
?

, , - .
. ,
(), ,
, , .
- .

69

| 2016

70

, ?
, ,
. .
, .
?
1, 3. ,
.
.
?
.
.
?
, ,
.
, . , ,
,
.
?
, (
), .
, , .
. ?
, ,
.
?
. .
.
, 2
.

?
.
?
, .

71

,
.
.
,
,
,
,
,
.

.

,
,


.
?

| 2016

72



.



.

Оценить